68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue 3, 2016, Pages 367-371

  Pyka, Thomas ^a   Weirich, Gregor ^a   Einspieler, Ingo ^a   Maurer, Tobias ^a   Theisen, Jörg ^a   Hatzichristodoulou, Georgios ^a   Schwamborn, Kristina ^a   Schwaiger, Markus ^a   Eiber, Matthias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

68Ga PSMA; Lung cancer; Prostate cancer; Pulmonary metastasis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PSMA HBED CC GA 68; TRACER; UNCLASSIFIED DRUG; EDETIC ACID; GALLIUM; N,N'-BIS(2-HYDROXY-5-(ETHYLENE-BETA-CARBOXY)BENZYL)ETHYLENEDIAMINE N,N'-DIACETIC ACID; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG LESION; LUNG METASTASIS; LUNG TUBERCULOSIS; MALE; PET-CT SCANNER; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMPLICATION; IMAGE PROCESSING; LUNG DISEASES; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; SECONDARY; SYNTHESIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; DIAGNOSIS, DIFFERENTIAL; EDETIC ACID; GALLIUM RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 84960081966     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.164442     Document Type: Article

References (23)

1. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50: 472-483.
2. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostatespecific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1: 18-28.
3. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3: 81-85.
4. Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents. Mol Pharm. 2009;6: 790-800.
5. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56: 668-674.
6. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42: 197-209.
7. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23: 688-697.
8. Schwenck J, Tabatabai G, Skardelly M, et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging. 2015;42: 170-171.
9. Krohn T, Verburg FA, Pufe T, et al. [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: An important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42: 210-214.
10. Moschini M, Sharma V, Zattoni F, et al. Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy. Eur Urol. 2016;69: 135-142.
11. Goodman OB Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castrationresistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17: 34-39.
12. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol. 2000;31: 578-583.
13. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143: E93S-120S.
14. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: Utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1): S5-S10.
15. Kessler RM, Ellis JR Jr, Eden M. Analysis of emission tomographic scan data: Limitations imposed by resolution and background. J Comput Assist Tomogr. 1984;8: 514-522.
16. Schäfer M, Bauder-Wust U, Leotta K, et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2: 23.
17. Souvatzoglou M, Eiber M, Martinez-Moeller A, et al. PET/MR in prostate cancer: Technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013;40(suppl 1): S79-S88.
18. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59: 3192-3198.
19. Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol. 2008;21: 1421-1427.
20. Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10: E0125924.
21. Hlouchová K, Barinka C, Klusak V, et al. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem. 2007;101: 682-696.
22. Tykvart J, Schimer J, Jancarik A, et al. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem. 2015;58: 4357-4363.
23. Tykvart J, Barinka C, Svoboda M, et al. Structural and biochemical characterization of a novel aminopeptidase from human intestine. J Biol Chem. 2015;290: 11321-11336.